Skip to main content
. Author manuscript; available in PMC: 2019 Jul 23.
Published in final edited form as: AAPS J. 2019 Feb 13;21(2):30. doi: 10.1208/s12248-019-0303-4

Fig. 8. The effect of PKA activator Bt2-cAMP on OAT3 ubiquitination.

Fig. 8.

(a). Top panel: hOAT3-expressing cells were treated with the Bt2-cAMP (1μM or 10μM, 30min). Cells were then treated with the PKC activator PMA (1 μM) for 30 min to enhance hOAT3 ubiquitination. hOAT3 was pulled down by anti-Myc antibody (hOAT3 was tagged with the Myc epitope), with subsequent immunoblotting (IB) using anti-ubiquitin antibody. Bottom panel: The identical immunoblot from Fig. 8a, Top panel was reprobed by anti-Myc antibody. (b). Densitometry analyses of results from Fig. 8a. The values are mean ± S.D. (n = 3). *P<0.05.